Edison Investment Research is terminating coverage on ReNeuron Group (RENE). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
Edison Investment Research Limited Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ 27-Nov-2023 / 08:53 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 27 November 2023 Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEX™, its proprietary stem cell-derived exosome delivery platform. The key operational update from the period included in vivo data...
ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEX(TM), its proprietary stem cell-derived exosome delivery platform. The key operational update from the period included in vivo data, marking a crucial step towards validating CustomEX(TM) and distinguishing it from peers in the exosome delivery space due to its cellular and tissue-targeting capabilities. As of 30 September 2023, ReNeuron had a cash balance of £5.1m, which we estimate sh...
ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While the precise nature of the data is yet to be disclosed, we view the update as an encouraging sign and believe that it could improve traction for discussions for collaborations and partnerships, a key near-term goal for the company. ReNeuron now aims to broaden its capabilities by focussing on the functional delivery of specific therapeutics payloa...
ReNeuron’s FY23 results provide a recap of financial and operational highlights from the period. Following the restructuring announcement in January 2023, the company’s focus rests on its proprietary stem cell-derived exosome platform, CustomEx. In vivo animal studies to validate the platform’s capabilities are ongoing, and ReNeuron plans to release readout data in H2 CY23, which we anticipate could be a key catalyst and generate traction for partnerships. Due to the macroeconomic environment, m...
25th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv...
In January, the company restructured the business to prioritise the generation of new exosome data. In our view, the core investment hypothesis remains intact, and we believe that the selective delivery of complex drug modalities could be highly attractive to partners. New exosome data will be key to unlocking partnerships and provide a route beyond the current cash runway into 2024. Consequently, we have reinstated our Buy rating with a lower target price of 70p.
Two Directors at Reneuron Group bought/maiden bought 142,128 shares at between 10p and 12p. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
ReNeuron Group has presented encouraging preclinical data surrounding the company’s conditionally immortalised induced pluripotent stem cell (CI iPSC) line. The results show that, using the group’s proprietary conditional immortalisation technology, ReNeuron can achieve enhanced control of growth and survival of CI-iPSC-derived cells, including Schwann cells, providing a potentially key differentiator over traditional iPSCs. While we acknowledge that these are early stage results, the latest dat...
With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from Fosun Pharma as part of a technology transfer and supply agreement. ReNeuron pared back its operating losses (£4.3m in H123, down from £6.1m in H122), largely with reduced clinical trial-related costs following the company’s strategic refocus on exosomes. ReNeuron ...
ReNeuron is a UK-based stem cell research company now strategically re-focused on the development of its exosome drug delivery technologies. Recent encouraging preclinical proof-of-concept data demonstrated the potential of ReNeuron’s exosomes to deliver complex therapeutic payloads with high tissue specificity. Drug delivery remains a major challenge in both central nervous system (CNS) and cell and gene drug development, and we view these as key markets for ReNeuron to offer differentiation. P...
ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over conventional human embryonic kidney-derived (HEK) exosomes. The company’s CustomEx exosomes displayed a minimum 10-fold increase in cellular uptake across three cell types (endothelial, neural and epithelial) compared to HEK-derived exosomes, with an 18-fold increase observed in endotheli...
ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. The company expects to report some data by March 2022, which could potentially open the way to a crucial partnering deal. Full efficacy data at six months post-treatment should be available around the middle of 2022. Our valuation remains £190m.
ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. The company expects to report some data by March 2022, which could potentially open the way to a crucial partnering deal. Full efficacy data at six months post-treatment should be available around the middle of 2022. Our valuation remains £190m.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.